Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,668 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
PARADIGM - French Regulatory Clearance 2 pages 183.1KB
Regulatory Filings Classification · 52% confidence The document is a corporate press release announcing regulatory clearance from the French National Agency for Medicines and Health Products Safety for a clinical trial. It is not a financial report (e.g., earnings release, annual or interim report), not a proxy or voting-related document, not a management change, not share issuance or M&A, nor a detailed ESG or investor presentation. It is a general regulatory announcement about clinical trial authorisation, so it falls under the fallback category “Regulatory Filings” (RNS).
2026-06-09 English
Change of Director's Interest Notice 2 pages 276.4KB
Director's Dealing Classification · 95% confidence The document is titled “Appendix 3Y Change of Director’s Interest Notice” and follows ASX’s Appendix 3Y format, disclosing a director’s personal share transaction (11,000 shares acquired). This is a standard insider dealing report. Therefore, it should be classified under Director's Dealing (DIRS).
2026-06-05 English
Statement of CDIs on issue - AVR 3 pages 12.9KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 4A filing (“Statement of CDIs on issue”) showing monthly changes in CHESS Depositary Interests and underlying securities, including numbers on issue at month end, net differences, and reasons for change (common stock issuance, CDI transfers). This is a capital change announcement regarding share issues and transfers, which falls under Share Issue/Capital Change (SHA).
2026-06-05 English
Notification of cessation of securities - AVR 4 pages 15.4KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3H “Notification of cessation of securities,” detailing changes in the company’s issued capital (expiry and lapse of options), which constitutes a capital structure change rather than an earnings release or management change. It specifically reports cessation of securities (unquoted options) and updated issued capital tables, fitting the “Share Issue/Capital Change” category.
2026-06-02 English
424B3
Capital/Financing Update Classification · 87% confidence The document is a Current Report on Form 8-K filed by the company pursuant to Section 13/15(d) of the Exchange Act. Item 1.01 describes the entry into a material definitive agreement for a sales agreement with TD Securities under which the company may offer and sell up to $250 million of its common stock in an at-the-market offering. This is a financing activity updating shareholders on capital raising and changes to the company’s capital structure. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-26 English
Prospectus Supplement and Sales Agreement 110 pages 710.5KB
Capital/Financing Update Classification · 88% confidence The document is a detailed prospectus supplement and sales agreement filed pursuant to Rule 424(b)(5) for an “at-the-market” equity offering under Rule 415, describing the terms of a new share issuance of up to $250 million. This is a fundraising/financing activity, matching the Capital/Financing Update category.
2026-05-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.